



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/518,390	10/25/2005	Virginie Louvain	263989US0PCT	2517
22850	7590	02/03/2011		
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P. 1940 DUKE STREET ALEXANDRIA, VA 22314			EXAMINER TSAY, MARSHA M	
			ART UNIT	PAPER NUMBER
			1656	
			NOTIFICATION DATE	DELIVERY MODE
			02/03/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

Office Action Summary

Application No.

10/518,390

Applicant(s)

LOUVAIN ET AL.

Examiner

Marsha M. Tsay

Art Unit

1656

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 November 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 3.9.10 and 18-22 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 3.9.10 and 18-22 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 30 December 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
- 1) ☒ Certified copies of the priority documents have been received.
 - 2) ☐ Certified copies of the priority documents have been received in Application No. _____.
 - 3) ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-946)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

This Office action is in response to Applicants' remarks received November 18, 2010.

Applicants' arguments have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous Office actions are hereby withdrawn.

Claims 1-2, 4-8, 11-17, 23-38 are canceled. Claims 3, 9-10, 18-22 are currently under examination.

Priority: The request for priority to FRANCE 0208299, filed July 3, 2002, is acknowledged. A certified copy of the foreign priority document has been filed in this case on December 30, 2004 and is in a non-English language.

As an initial matter, it should be noted that the Office action of January 14, 2010 (p. 7) and the Office action of August 18, 2010 (p. 6-7), inadvertently referred to the sequence Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇ as instant SEQ ID NO: 2 under the "Reply" sections of said Office actions, when it should have read as instant SEQ ID NO: 9. The sequence Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇ (i.e. Val-Pro-Arg-Ala-Val-Gly), is correctly referred to as SEQ ID NO: 9 in the instant action.

Objections and Rejections

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person

having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 3, 18, 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Himmelspace et al. (US 6573071; previously cited). For examination purposes, claim 3 has been interpreted as an enhanced human Factor X analogue comprising the sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9), wherein said human factor X analogue has at least one of the enhancements recited in claim 3. Therefore, any reference disclosing a Factor X analogue comprising at least instant SEQ ID NO: 9 is believed to be relevant art.

Himmelspace et al. disclose a Factor X analogue, having a modified processing site, comprising the sequence Gly228 to Ile235 having the sequence Gly228-R6-R5-R4-R3-R2-Arg234-R1 (col. 83, see also SEQ ID NO: 27), wherein

- a) R1 is an amino acid selected from the group consisting of Ile, Val, Ser, Thr, and **Ala**,
- b) R2 is an amino acid selected from the group consisting of **Pro**, Gly, Lys, and Arg,
- c) R3 is an amino acid selected from the group consisting of Phe, Lys, Met, Gln, Glu, Ser, **Val**, Arg, and Pro

Therefore, Himmelspace et al. disclose a Factor X analogue comprising the sequence Gly228-R6-R5-R4-**Val232-Pro233-Arg234-Ala235-Val236-Gly237**, wherein the amino acids in bold correspond to the instant thrombin-cleavable sequence Val-Pro-Arg-Ala-Val-Gly. Himmelspace et al. also disclose a preparation comprising said Factor X analogue having a processing site as noted by the sequence noted above, therefore said preparation would be a medicinal product (col. 84 lines 60-67). Himmelspace et al. do not explicitly teach a Factor X analogue comprising Val-Pro-Arg-Ala-Val-Gly (instant SEQ ID NO: 9).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to make a Factor X analogue, having a modified processing site, comprising Gly228-R6-R5-R4-**Val232-Pro233-Arg234-Ala235-Val236-Gly237**, wherein the amino acids in bold correspond to the instant sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9) (claims 3, 22). The motivation to do so is given by Himmelspace et al., which disclose Factor X analogues can comprise a modified processing site having an amino acid sequence formula that encompasses instant SEQ ID NO: 9.

While Himmelspace et al. disclose a general group of Factor X analogues, the instant Factor X analogue is within the scope of Factor X analogues disclosed by Himmelspace et al. since upon cleavage of the Factor X analogue of Himmelspace et al. as noted in the paragraph above, one of ordinary skill would obtain a Factor Xa analogue since the Factor X analogue of Himmelspace et al. can comprise instant SEQ ID NO: 9 (instant claim 18). It should also be noted that the phrase "can be obtained by cleavage of a Factor X analogue by thrombin" is also describing a property of the factor X analogue which would be present as long as SEQ ID NO: 9 is encompassed within the Factor X analogue.

Additionally, regarding the enhancements recited in claim 3, it should be noted that Himmelspace et al. disclose that their Factor X/Xa analogues have high stability (col. 4 lines 29-36) and displays Factor Xa activity (col. 5 lines 36-40), which would be within the scope of the instant enhancements.

The reasons for maintaining the Himmelspace et al. reference are the same as previously noted and for the reasons noted below. Applicants' remarks received November 18, 2010, will be addressed herein.

(1) In their remarks previously received and received on November 18, 2010, Applicants assert the object of the present application is a factor X, initially with a native activation site, in which said activation site is mutated between the position 232 and 237.

The native sequence of the activation site of factor X comprises the sequence:

Gly₂₂₈-Asn₂₂₉-Asn₂₃₀-Asn₂₃₁-Leu₂₃₂-Thr₂₃₃-Arg₂₃₄-Ile₂₃₅-Val₂₃₆-Gly₂₃₇

The factor X according to the present invention is mutated so that the sequence Leu₂₃₂-Thr₂₃₃-Arg₂₃₄-Ile₂₃₅-Val₂₃₆-Gly₂₃₇ of the native activation site of factor X is replaced with the sequence Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇.

The factor X analogue of the present invention thus comprises, in its activation site, the sequence:

Gly₂₂₈-Asn₂₂₉-Asn₂₃₀-Asn₂₃₁-**Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇**

The Examiner alleges that Himmelspace et al. disclose a factor X analogue comprising the sequence:

Gly₂₂₈-**R6**₂₂₉-R5₂₃₀-R4₂₃₁-Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇

According to Himmelspace et al., R4 can be Asn, R5 can be Asn, but Himmelspace et al. do not disclose the presence of Asn at position 229 (amino acid R6).

(2) Himmelspace et al. fail to disclose or suggest a factor X analogue having the sequence Leu-Thr-Arg-Ile-Val-Gly (SEQ ID NO: 1) of the activation site of native factor X replaced with the sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9) with sufficient specificity

and the artisan would have no reason to select this factor X analogue from the extensive list of alternative factor X analogues, much less an expectation of the beneficial results flowing from the same. Indeed, as stated above Himmelspace et al. merely disclose an extensive list of alternative factor X analogues and provides a generic disclosure, which can definitely not be considered as anticipating the very specific and particular combination of substituent which characterizes the analogue of factor X according to the present application.

(3) Applicants also assert that the present invention provides extraordinary and unexpected results, i.e. provides a high amidolytic activity, interacts with factor Va and activate prothrombin, has a higher half time than native activated factor X, has a procoagulant activity, and establishes an autoamplification of thrombin generation. Applicants submit the declaration under 37 CFR 1.132 by Dr. Bernard Le Bonniec for support. The skilled artisan would certainly appreciate that the efficiency of cleavage is conditioned by the nature of the amino acids framing the cleavage site of factor X, and more specifically by the residues P_3 - P_2 - P_1 - P'_1 - P'_2 - P'_3 of the activation site, the cleavage occurring between the residues P_1 and P'_1 . The residues P'_1 to P'_3 are thus involved in the catalytic activity of factor X after activation.

Applicant's arguments filed have been fully considered but they are not persuasive.

(1) Reply: It should be noted that the thrombin-cleavable sequence is the sequence Pro-Arg-Ala (specification p. 6 lines 14-17). Therefore, even if Himmelspace et al. do not teach Asn at position 229 (amino acid R6), the thrombin-cleavable sequence Pro-Arg-Ala is still present and would be cleaved by thrombin. It should be noted again, that Himmelspace et al. disclose that their factor X analogue is cleavable by factor IIa (i.e. thrombin), which is the serine protease recited in instant claim 18. Therefore, regardless of what the other amino acids are outside of the

6-mer sequence, Leu₂₃₂-Thr₂₃₃-Arg₂₃₄-Ile₂₃₅-Val₂₃₆-Gly₂₃₇ (instant SEQ ID NO: 1), since Himmelspach et al. disclose that the sequence can be replaced by Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇ (instant SEQ ID NO: 9), it would be reasonable for one of ordinary skill to know that the instant invention is within the scope of the Himmelspach et al. invention.

Additionally, Applicants are reminded that although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993) (Claims to a superconducting magnet which generates a "uniform magnetic field" were not limited to the degree of magnetic field uniformity required for Nuclear Magnetic Resonance (NMR) imaging. Although the specification disclosed that the claimed magnet may be used in an NMR apparatus, the claims were not so limited.); Constant v. Advanced Micro-Devices, Inc., 848 F.2d 1560, 1571-72, 7 USPQ2d 1057, 1064-1065 (Fed. Cir.), cert. denied, 488 U.S. 892 (1988) (Various limitations on which appellant relied were not stated in the claims; the specification did not provide evidence indicating these limitations must be read into the claims to give meaning to the disputed terms.); Ex parte McCullough, 7 USPQ2d 1889, 1891 (Bd. Pat. App. & Inter. 1987) (Claimed electrode was rejected as obvious despite assertions that electrode functions differently than would be expected when used in nonaqueous battery since "although the demonstrated results may be germane to the patentability of a battery containing appellant's electrode, they are not germane to the patentability of the invention claimed on appeal."). MPEP 2145. In this instance, claim 3 simply recites an enhanced human factor X analogue that only has to comprise SEQ ID NO: 9. Therefore, any factor X protein comprising SEQ ID NO: 9 would naturally have to have all of

the enhancements currently recited in claim 3. If R6 is truly essential to the instant human factor X analogue's activity, then the claim needs to be amended to reflect that.

(2) Reply: Since Himmelspace et al. disclose a finite number of Factor X analogues that exhibit high stability and can be activated to factor Xa without using any of the conventional proteases, it would be reasonable and obvious for one of ordinary skill to try and choose from the finite number of substitutions disclosed by Himmelspace et al. in order to arrive at a Factor X analogue comprising the sequence Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇ (instant SEQ ID NO: 9), which is cleavable by Factor IIa, since these components are disclosed by Himmelspace et al. See also MPEP 2141.

Additionally, a claimed compound would have been obvious where it was obvious to try to obtain it from a finite and easily traversed number of options that was narrowed down from a larger set of possibilities by the prior art, and the outcome of obtaining the claimed compound was reasonably predicted. *Bayer Schering Pharma AG. v. Barr Labs., Inc.*, 575 F.3d 1341 (Fed. Cir. 2009). In this instance (and as noted above), Himmelspace et al. disclose a finite number of amino acids that each of R1 (5 possibilities), R2 (4 possibilities), and R3 (9 possibilities) can be. Therefore, since it was known at the time of the invention that the thrombin-cleavable sequence is essentially a 3-mer sequence and Himmelspace et al. disclose Factor X analogues with improved stability and activity can be arrived at using the combinations of R1, R2, and R3, it would be reasonable for one of ordinary skill to arrive at the sequence Gly₂₂₈-R6-R5-R4-**Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇** and further expect said Factor X analogue comprising said sequence Gly₂₂₈-R6-R5-R4-**Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇** to have improved stability and activity because the thrombin-cleavable sequence Pro-Arg-Ala is

present and would be cleaved by thrombin. It should be noted again, that Himmelspace et al. disclose that their factor X analogue is cleavable by factor IIa (i.e. thrombin), which is the serine protease recited in instant claim 18. Therefore, regardless of what the other amino acids are outside of the 6-mer sequence, Leu₂₃₂-Thr₂₃₃-Arg₂₃₄-Ile₂₃₅-Val₂₃₆-Gly₂₃₇ (instant SEQ ID NO: 1), since Himmelspace et al. disclose that the sequence can be replaced by Val₂₃₂-Pro₂₃₃-Arg₂₃₄-Ala₂₃₅-Val₂₃₆-Gly₂₃₇ (instant SEQ ID NO: 9), it would be reasonable for one of ordinary skill to know that the instant invention is within the scope of the Himmelspace et al. invention.

(3) Reply: Regarding Applicants' unexpected results and the declaration under 37 CFR 1.132, it should be noted that the instant unexpected properties would be present in the factor X analogue of Himmelspace et al. even though Himmelspace et al. did not recognize the same properties because Himmelspace et al. disclose the instant thrombin-cleavable sequence, i.e. Pro-Arg-Ala, anyway. It should further be noted that it is not necessary in order to establish a prima facie case of obviousness . . . that there be a suggestion or expectation from the prior art that the claimed [invention] will have the same or a similar utility as one newly discovered by applicant,..." 919 F.2d at 693, 16 USPQ2d at 1901. See also MPEP 2144.

Further, the fact that Appellant has recognized another advantage which would flow naturally from following the suggestion of the prior art cannot be the basis for patentability when the differences would otherwise be obvious." Ex parte Obiaya, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985). See also MPEP 2145.

See also the replies of (1) and (2).

For at least these reasons, the 103(a) rejection is maintained.

Claims 19-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Himmelspace et al. (US 6573071; previously cited). The teachings of Himmelspace et al. are outlined above. Himmelspace et al. further disclose nucleic acid molecules, expression vectors, and host cells that can be used to express the Factor X analogues disclosed by Himmelspace et al. (col. 17-28). Himmelspace et al. do not explicitly teach a nucleic acid molecule encoding the thrombin-cleavable sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to prepare a Factor X analogue having the thrombin-cleavable sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9) as disclosed by Himmelspace et al. by constructing expression plasmids for the preparation of Factor X analogue for expression in host cells (claims 19-21). The motivation to do so is given by Himmelspace et al., which disclose that Factor X analogues having the thrombin-cleavable sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9) can be prepared by constructing expression plasmids followed by transformation into a host cell for expressing a Factor X analogue protein.

The Himmelspace et al. reference is still maintained over claims 19-21 because it is believed to be relevant art for the reasons noted above.

Claims 9-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Himmelspace et al. (US 6573071; previously cited). The teachings of Himmelspace et al. are outlined above. Himmelspace et al. further disclose Factor X/Xa is an important component of the prothrombinase complex and may be used to treat patient suffering from blood coagulation

disorders, i.e. hemophilia (col. 3-4). Himmelspace et al. do not explicitly teach a preparation comprising a Factor X analogue with the thrombin-cleavable sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9) and a method of treating hemophilia utilizing said Factor X analogue.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to administer the Factor X analogue of Himmelspace et al. to a patient for the treatment of hemophilia because Himmelspace et al. disclose Factor X/Xa which exhibits high stability and can be activated to Factor Xa without use of conventional proteases (col. 4 lines 30-35), i.e. modified to have the thrombin-cleavable sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9), can be administered to treat patients suffering from hemophilia (claims 9-10).

The Himmelspace et al. reference is still maintained over claims 9-10 because it is believed to be relevant art for the reasons noted above.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marsha M. Tsay whose telephone number is (571)272-2938. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath N. Rao can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Marsha M. Tsay/
Examiner, Art Unit 1656

January 31, 2011